



Global Research & Development

Internal Ref: SAN 9628
19 November 2007

Dr Noël Wathion European Medicines Agency (EMA) Loading Dock Ontario Way Canary Wharf London, E14 4HB UK	THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.
--	--

Dear Dr Wathion,

**Re: Exubera inhalation powder, pre-dispensed (1 and 3 mg): EU/1/05/327/001-18 –
Notice of Intention to Cease Marketing of Product**

Pfizer announced on 18th October, 2007 that it will be returning the worldwide rights for Exubera to Nektar, the company that initiated the development of the inhaled insulin technology. While Exubera remains a well tolerated and effective medicine, it has not met the needs of prescribing doctors in managing patients with diabetes to the extent anticipated.

Following this announcement, Nektar announced on 13th November, 2007 that it is looking for a new partner for Exubera. As a result, Pfizer will make Exubera available until January 16, 2008, with the understanding that, if Nektar is able to find a new partner, Pfizer will make the product available beyond that date. If a new partner is selected, Pfizer and Nektar will work together to transfer Pfizer's interest (including the Marketing Authorisation) to the new partner. In the meantime, Pfizer intends to continue its post-marketing approval commitments for Exubera.

Pfizer's decision to stop marketing Exubera is based only on commercial reasons. This is not a product recall, nor the result of any safety signal.

Pfizer is currently communicating with healthcare professionals involved in diabetes management. Advice has been provided for the management of patients currently being treated with Exubera and potential new patients.

Page 1 of 2



1001324 rev 1/06

2005
AWARDED TO PFIZER LIMITED

Registered in England: No 526209
Registered Office: Ramsgate Road
Sandwich, Kent CT13 9NJ, UK

Patients should contact their doctor to discuss treatment options available to them.

Pfizer is advising doctors who are managing clinical trials using Exubera of the specific arrangements for each clinical trial. **Subjects taking part in clinical trials should contact their study doctor so they can understand the effect of Pfizer's decision on their study participation.**

Pfizer has agreed that this letter may be published on the EMEA website in the interest of transparency.

Yours sincerely,

Director
Worldwide Regulatory Strategy - EU

0100000707169712.D\Approved\19-Nov-2007 04:45

Page 2 of 2

1901324 rev 1.06



Registered in England: No 526209
Registered Office: Ramsgate Road
Sandwich, Kent CT13 9NJ, UK